androgen receptor pathway inhibitor

Metabolic Dysfunction Following Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer: Clinical Implications and Risks

This study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.